LifeMD Inc

NASDAQ:LFMDUnited States

Amortization of debt discount - - 0.01 0.01 Loss on debt extinguishment - - - 0.01 Financing transactions expense - 0.01 0.01 0.02 Litigation costs 0.02 0.01 0.03 0.04 Inventory and reserve adjustments on discontinued products - - 0.02 0.01 Severance costs 0.01 - 0.03 - Acquisitions expenses - - - - Insurance acceptance readiness 0.01 - 0.03 - Sarbanes Oxley readiness - - 0.01 - Accrued interest on Series B Convertible Preferred Stock - - - 0.02 Foreign exchange (gain) loss 0.01 0.01 0.02 0.02 Taxes 0.03 - 0.03 - Dividends 0.02 0.05 0.07 0.12 Stock-based compensation expense 0.06 0.10 0.22 0.27 Net loss attributable to noncontrolling interests - 0.03 - 0.07 Adjusted EPS $ 0.09 $ 0.08 $ 0.16 $ 0.20 ===== ===== ===== ===== Reconciliation of Telehealth GAAP Net Loss to Telehealth Adjusted EBITDA (in whole numbers, unaudited) Three Months Ended Nine Months Ended September September 30, 30, --------------------------- ------------------------------ 2024 2023 2024 2023 ------------ ------------- ------------- --------------- Net loss attributable to common shareholders $(4,612,049) $(10,044,756) $(20,401,514) $(27,731,584) Interest expense (excluding amortization of debt discount) 456,151 593,013 1,263,120 1,229,576 Depreciation, amortization and accretion expense 1,707,151 1,150,718 4,555,921 3,176,361 Amortization of debt discount 100,443 79,653 301,331 233,495 Loss on debt extinguishment - - - 325,198 Financing transactions expense - 305,424 323,372 735,501 Litigation costs (a) 644,170 420,404 1,322,501 1,426,330 Inventory and reserve adjustments on discontinued products 85,000 - 651,142 232,630 Severance costs 621,391 7,692 1,142,068 7,692 Acquisitions expenses - 86,942 - 127,138 Insurance acceptance readiness 391,803 8,094 1,361,637 66,634 Sarbanes Oxley readiness 203,342 48,576 386,470 48,576 Accrued interest on Series B Convertible Preferred Stock - 39,884 - 506,991 Foreign exchange (gain) loss - - - - Taxes - - - - Dividends 812,562 812,563 2,437,687 2,437,688 Stock-based compensation expense 2,394,235 3,318,253 9,129,841 8,843,736 Net loss attributable to noncontrolling interests (345,767) 839,288 (187,729) 2,247,055 Telehealth Adjusted EBITDA $ 2,458,433 $ (2,334,252) $ 2,285,847 $ (6,086,983) ========== =========== =========== =========== (a) For the three and nine months ended September 30, 2024, the Company included litigation costs related to a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (the Marden v. LifeMD, Inc. case), as disclosed in the Company's Form 10-Q for the third quarter ended September 30, 2024 and a heavily negotiated executive separation agreement. For the three and nine months ended September 30, 2023, the Company included litigation costs related to a purported breach of an investment bank engagement concerning potential debt financing (the William Blair LLC v. LifeMD, Inc. case) and a purported breach of a consulting services agreement for strategic and corporate development services (the Harborside Advisors LLC v. LifeMD, Inc. case), as disclosed in the Company's Form 10-K for the fiscal year ended December 31, 2023 and filed on March 11, 2024.

LifeMD(R) Launches Affiliated Pharmacy to Drive End-to-End Patient Care and Operational Efficiency

State-of-the-Art Pharmacy Completes LifeMD's End-to-end Healthcare Platform, Supporting 5,000 Daily Orders, Improving Operating Margins, and Enabling Curated Care Journeys